7 results about "Hybrid protein" patented technology

Are disclosed peptide binding the CD71 transferring receptor, genetically engineered DNA-binding proteins from starved cells (DPS), and hybrid protein-nucleic acid complexes having the capability of being identified and taken up by the human CD71 receptor, and which can be used in targeted delivery of nucleic acid in cells.

A method for reducing mortality resulting from viral infection, reducing viral load resulting from viral infection, or increasing immunity to viral infection in a subject is described. The method comprises administering a hybrid protein comprises a first domain comprising a sequence encoding a surface protein of an enveloped RNA virus and a second domain comprising a sequence encoding an ectodomain of a type 2 transmembrane domain protein, wherein the second domain is located at the C-terminal of the first domain. The hybrid protein or an mRNA encoding such protein can be used as a vaccine against the infection of the enveloped RNA virus.

The present invention provides means and methods for treating MVT and associated and / or similar conditions. The invention therefore provides hybrid proteins for targeted delivery of plasminogen activators to platelet-VWF complexes, or alternatively to the site where these are located, in a fibrin-independent manner. The invention further provides therapeutic methods for conditions that can be prevented or treated by local delivery / stimulation of plasminogen activation to sites of microvascular occlusion.

The invention provides a mixed protein base material and application thereof, and the mixed protein base material comprises the following components in percentage by mass: 25%-80% of whey protein, 15%-70% of collagen peptide, 2%-4% of moderately hydrolyzed whey protein, 1%-2% of highly hydrolyzed whey protein and 2%-4% of whey protein rich in milk phospholipid membrane. According to the mixed protein base material provided by the invention, an oil-water interface of an emulsion is jointly stabilized through proteins with different molecular weights and compositions, the emulsion and microcapsules can be effectively stabilized, and fat-soluble functional factors are further delivered by utilizing the obtained emulsion and microcapsules, so that the stability of the fat-soluble functional factors can be improved; and the bioavailability can be improved.

A method for reducing mortality resulting from viral infection, reducing viral load resulting from viral infection, or increasing immunity to viral infection in a subject is described. The method comprises administering a hybrid protein comprises a first domain comprising a sequence encoding a surface protein of an enveloped RNA virus and a second domain comprising a sequence encoding an ectodomain of a type 2 transmembrane domain protein, wherein the second domain is located at the C-terminal of the first domain. The hybrid protein or an mRNA encoding such protein can be used as a vaccine against the infection of the enveloped RNA virus.

The invention relates to a recombinant RE15mR and EJ17zipR hybrid protein with a structure as described in the specification, a recombinant DNA sequence for coding the recombinant hybrid protein, a vector containing the recombinant DNA sequence, and a eukaryotic or prokaryotic expression system transformed by using the recombinant DNA sequence. The invention also relates to the use of the recombinant hybrid protein as a component of bio-inks intended for bio-printing and as a component of biological materials. In addition, the invention also relates to the use of the recombinant DNA sequence, the vector and the eukaryotic or prokaryotic expression system for preparing the recombinant hybrid protein.

A hybrid protein comprises a first domain comprising a sequence encoding a surface protein of an enveloped RNA virus and a second domain comprising a sequence encoding an ectodomain of a type 2 transmembrane domain protein, wherein the second domain is located at the C-terminal of the first domain. The hybrid protein or an mRNA encoding such protein can be used as a vaccine against the infection of the enveloped RNA virus.